Two-day China healthcare tour: rising innovation bar, more sophisticated bd, and more verifiable aidd revenue

Overview

This report summarizes J.P. Morgan’s two-day tour of Chinese healthcare companies from May 18 to 19, 2026, covering aidd, biotech, and medtech companies. The report argues that four more positive structural changes are emerging in China’s healthcare sector: commercialization of ai platforms is becoming more visible, biotech innovation is shifting from fast-follow to differentiation, bd transactions are becoming standard for financing and globalization, and hospitals are accelerating adoption of surgical robots, ngs, and precision therapies such as targeted drugs / bispecifics / adcs.

Core views

The core view is that the competitive focus in China’s healthcare industry is shifting from low-cost R&D and rapid following to verifiable commercialization, differentiated mechanisms, and global partnership capabilities. Aidd companies are beginning to prove that ai can be a revenue driver, while traditional biotech companies are also embedding ai into early discovery processes; innovative drug companies are putting greater emphasis on unmet needs and novel mechanisms; bd structures help companies extend cash runway and reduce pressure from global clinical development; and hospital adoption of new technologies provides clinical validation scenarios for surgical robots, precision oncology treatment, and next-generation antibodies / conjugated drugs.

Analysis framework

The report uses on-site tours and management / expert interviews, with samples including aidd, biotech, and medtech companies in Beijing and Shanghai as well as lung cancer clinical experts. The analytical focus is not on traditional valuation models, but on judging industry momentum and company competitiveness through commercial partnerships, clinical data, pipeline differentiation, hospital procurement, and changes in clinical pathways.

Methodology notes

• Industry trendaidd commercialization validation

  From proof of concept to revenue driver

  The report treats whether ai drug discovery can generate real collaboration revenue, out-licensing, and internal pipeline advancement as an important basis for judging the investment value of aidd companies.

• Pipeline qualityDifferentiated innovation

  From fast-follow to novel mechanisms and unmet needs

  The report emphasizes that pipelines such as siRNA, molecular glue, BCL-2, TYK2, TYK2/JAK1, and IL-17 need to prove value through differentiated indications, mechanisms, and clinical data.

• Financing and globalizationbd/license-out/newco structure

  Use partnership deals to reduce funding pressure and expand overseas markets

  The report believes that China biotech is turning global partnerships, preclinical out-licensing, option fees, and NewCo structures into standardized tools for financing and internationalization.

• End-market validationHospital-side technology adoption

  Real-world adoption validates product roi and clinical value

  Robot installations, remote surgery volumes, ngs testing, and changes in targeted-treatment pathways are used to observe whether hospitals are truly accepting advanced medical technologies.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• XtalPi (2228.HK, NC)

  Representative company for aidd commercialization

  Strengths

  Covers modalities such as multispecific antibodies, peptides, and siRNA, has hundreds of ai models and 10,000+ ai agents, and disclosed a US$345 million collaboration with Eli Lilly.

  Weaknesses

  The report does not provide full details on recurring revenue structure, margins, or the pace of collaboration monetization.

  Comparison

  Compared with ai drug discovery companies still at the proof-of-concept stage, XtalPi places greater emphasis on platform revenue and validation through partnerships with large pharma companies.

  Risks

  Collaboration milestone delivery, platform replicability, R&D success rate, and customer concentration still need to be monitored.

• Harbour BioMed (2142.HK, NC)

  Traditional biotech adopting ai-native discovery and out-licensing through the Nona platform

  Strengths

  Integrates an ai-native discovery engine through Nona Biosciences to accelerate preclinical screening and internal pipeline generation, while emphasizing preclinical out-licensing and option-fee economics with AstraZeneca and BMS.

  Weaknesses

  Part of the value still depends on early-stage pipelines and partner optionality, and revenue visibility may be affected by transaction timing.

  Comparison

  Compared with a purely internal R&D model, Harbour BioMed places more emphasis on platform-based out-licensing and bd monetization.

  Risks

  There is uncertainty around global phase I data for CLDN18.2xCD3 TCE and long-acting TSLP mAb, as well as out-licensing terms and follow-up payments.

• METiS (7666.HK, NC)

  Aidd and mRNA drug platform company

  Strengths

  Uses the AiLNP, AiRNA, and AiTEM platforms to advance internal mRNA drug assets, optimize delivery solutions, and pursue out-licensing deals.

  Weaknesses

  As a newly listed company, its commercialization and clinical validation track record still needs more public data support.

  Comparison

  Compared with traditional biotech, METiS relies more on the synergy among ai platforms, delivery technologies, and an mRNA asset portfolio.

  Risks

  Risks include clinical success rates of mRNA assets, differentiation of delivery technology, out-licensing execution, and market acceptance.

• InnoCare (9969.HK, NC)

  Innovative drug company focused on hematologic cancers and autoimmune diseases

  Strengths

  1Q26 revenue grew 38.65%, and management believes the company is well positioned in hematologic cancers and autoimmune diseases; the BCL-2 inhibitor is running multiple monotherapy and combination trials, while TYK2, TYK2/JAK1, and IL-17 oral inhibitors have upcoming data catalysts.

  Weaknesses

  The report does not provide specific information on profitability, cash flow, or target price.

  Comparison

  Compared with earlier-stage biotech companies, InnoCare already has revenue growth and multiple clinical data milestones.

  Risks

  Risks include key clinical data missing expectations, competitive pressure from autoimmune / hematologic cancer pipelines, regulatory approval, and commercialization ramp-up.

• MicroPort MedBot (2252.HK, OW)

  Representative of medtech and end-market adoption of surgical robots

  Strengths

  Management reiterated 2026 guidance for 200 new robot installations, and Toumai Remote has completed 800+ remote surgeries, showing hospital recognition of the platform’s roi.

  Weaknesses

  The path from installed base to revenue, as well as consumables / service revenue and profitability, still needs validation.

  Comparison

  Compared with medical device companies still only at the R&D stage, MicroPort MedBot already has installations and remote surgery usage data as end-market validation.

  Risks

  Risks include hospital capex, tendering and reimbursement pressure, competing products, regulation of remote surgery, and installation delivery risk.

• Sirius Therapeutics、GluBio、Syneron、Deep Intelligent Pharma（private）

  Samples of unlisted innovative drug / aidd / novel-mechanism companies

  Strengths

  Sirius Therapeutics showed 90-95% Factor XI reduction for SRSD107 and plans phase III; GluBio is advancing molecular glue pipelines such as GLB-005 and GLB-007; Syneron controls R&D burn through AstraZeneca collaboration and Pfizer Ventures support; Deep Intelligent Pharma uses llm and multi-agent systems to drive its clinical cro business.

  Weaknesses

  Disclosure from private companies is limited, with insufficient detail on valuation, financials, and clinical progress.

  Comparison

  These companies reflect China biotech’s shift from pure fast-follow toward mechanism innovation, ai workflows, and more sophisticated bd financing.

  Risks

  Risks include early clinical failure, changes in the financing environment, uncertain bd terms, and relatively low transparency at private companies.

Key data

• Tour period2026-05-18至2026-05-19J.P. Morgan toured multiple Chinese healthcare companies in Beijing and Shanghai.
• XtalPi and Eli Lilly collaborationUS$345 millionThe report says the collaboration was reached in November 2025 and is used to demonstrate the commercialization capability of the aidd platform.
• XtalPi ai platform scale数百个ai模型、10,000+个ai agentsUsed to support discovery across modalities such as multispecific antibodies, peptides, and siRNA.
• InnoCare 1Q26 revenue growth38.65%Management believes the company is well positioned in hematologic cancers and autoimmune diseases.
• Sirius Therapeutics SRSD10790-95% Factor XI降低The company plans to conduct a phase III trial for SRSD107, and the report views this siRNA pipeline as differentiated.
• Syneron annual R&D burnUS$60-70 millionManagement said it is supported by the AstraZeneca partnership and Pfizer Ventures, reflecting a more efficient bd financing structure.
• MicroPort MedBot 2026 installation guidance新增200台机器人Management reiterated its 2026 installation target and disclosed that Toumai Remote has completed 800+ remote surgeries.
• MicroPort MedBot disclosed price and rating2252.HK / HK$27.30 / OWPrice as of the close on May 22, 2026.

Impact & implications

From an investment perspective, the report increases confidence in the medium- to long-term competitiveness of China’s healthcare sector, but opportunities are more concentrated in companies that can demonstrate commercial revenue, differentiated clinical value, global partnership capabilities, and real hospital adoption. The valuation narrative for aidd and innovative drug companies needs to shift from technology concepts to orders, out-licensing, clinical data, and cash runway; medtech companies, meanwhile, need to prove sustainable growth through installations, surgical volume, and hospital roi.

Risks

• Aidd revenue may still depend on a small number of large partnerships, and its sustainability and replicability need validation.
• Innovative drug pipelines face risks of clinical failure, safety issues, endpoint selection, and competition from peers, especially as first-line treatment settings require higher safety standards.
• Although bd, license-out, and NewCo structures can ease financing pressure, there is uncertainty around deal terms, milestone payments, and partner execution.
• Hospital-side technology adoption may be affected by budgets, tendering, reimbursement, physician training, and device roi validation.
• Chinese healthcare companies still face risks from regulation, geopolitics, overseas clinical development, and changes in capital market financing conditions.

What to watch

• Upcoming key data for InnoCare’s TYK2, TYK2/JAK1, and IL-17 oral inhibitors.
• Global phase I data for Harbour BioMed’s CLDN18.2xCD3 TCE and phase I data for its long-acting TSLP mAb.
• Aidd orders, collaboration revenue, out-licensing, and profit realization for XtalPi, METiS, and Deep Intelligent Pharma.
• Whether MicroPort MedBot can achieve its 2026 target of 200 new robot installations and continue increasing Toumai Remote surgery volume.
• The pace of phase III advancement for Sirius Therapeutics’ SRSD107 and clinical validation of the Factor XI target.
• The speed of real-world adoption of ngs testing, targeted therapies, bispecifics, and TROP2 ADCs in oncology treatment pathways.